Abstract: Chlorogenic are used in preparing a drug for preventing or blocking brain and/or bone metastases of lung cancer. The chlorogenic acid can effectively prevent or block metastasis of tumor cells of a patient with lung cancer, such as small cell lung cancer, squamous cell lung cancer, and lung adenocarcinoma.

Abstract: A drug for use in combination for treating high-grade brain tumors in response to ineffective standard treatment for postoperative recurrence. The drug for includes chlorogenic acid and temozolomide of the same or different unit preparations for simultaneous or separate administration, and a pharmaceutically acceptable carrier. A pharmaceutical composition includes chlorogenic acid and temozolomide can be used to prepare a drug for treatment of high-grade brain tumors for which standard treatment for postoperative recurrence is ineffective.

Abstract: A drug combination for treatment of amyotrophic lateral sclerosis includes chlorogenic acid, vitamin E, vitamin C, coenzyme Q10, and creatine phosphate sodium, as well as pharmaceutically acceptable carriers, in which chlorogenic acid, vitamin E, vitamin C, coenzyme Q10, and creatine phosphate sodium are unit preparations having same or different specifications, that are simultaneously or separately administrated. The combination of chlorogenic acid, vitamin E, vitamin C, coenzyme Q10, and creatine phosphate sodium shows a synergistic effect on amyotrophic lateral sclerosis, thus provides a combination with excellent therapeutic effect on amyotrophic lateral sclerosis, which delays the progression of amyotrophic lateral sclerosis.

Abstract: The invention relates to quinazoline compounds, the preparation method, use, and the pharmaceutical composition thereof. The said quinazoline compounds, which are represented by Formula (I), are phosphatidylinositol 3-kinase (PI3K) inhibitors, and can be applied to prevent and/or treat PI3K activity-related diseases, such as cancer, immune diseases, cardiovascular diseases, viral infections, inflammation, metabolism/endocrine function disorders or neurological diseases.

Abstract: The present invention discloses a nicotinyl alcohol ether derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to nicotinyl alcohol ether derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.

Abstract: A pharmaceutical composition includes chlorogenic acid and coumaroylquinic acid. It can be used for preparing a reversing agent for tumor multi-drug resistance and a PD-1/PD-L1 inhibitor. The combined use of chlorogenic acid and coumaroylquinic acid exhibits a synergistic effect, effectuating a good reversing effect on the drug resistance of a tumor cell strain that produces multi-drug resistance for chemotherapeutic drugs and immunotherapeutic drugs, which may effectively inhibit PD-1/PD-L1 expression in drug-resistant B16 melanoma and drug-resistant Lewis lung cancer mice transplantation tumor tissue, and may effectively proliferate CD4+T and CD8+T cells in drug-resistant B16 melanoma mice and Lewis lung cancer mice.

Abstract: The present invention discloses a benzyl phenyl ether derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to benzyl phenyl ether derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.

Abstract: The present invention relates to a benzamide compound and a preparation method, use and pharmaceutical composition thereof. The benzamide compound represented by formula (I) is a STAT3 inhibitor, and can be used to prevent and/or treat a disease related to STAT3 activity, such as a tumor, autoimmune disease, renal disease, cardiovascular disease, inflammation, metabolic/endocrine dysfunction, and neurological disease.

Abstract: The present invention discloses a nicotinyl alcohol ether derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to nicotinyl alcohol ether derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.

Abstract: A method includes obtaining, by a control platform, request information, where the request information carries an identifier of user equipment (UE) and an identifier of a vehicle-mounted device, and sending indication information to the UE based on the request information, where the indication information instructs the UE to disable or enable a vehicle-to-pedestrian (V2P) function to forbid or allow the UE to transmit a V2P message.

Abstract: The present invention discloses a phenylate derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to phenylate derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.

Abstract: A communication mode selection method includes transmitting, in a first communication mode, a vehicle-to-everything (V2X) service between a leading vehicle and a following vehicle that are in a vehicle platoon, obtaining, signal quality of the first communication mode, when the signal quality of the first communication mode meets a first preset condition, sending, a configuration instruction to the following vehicle, where the configuration instruction is used to instruct the following vehicle to communicate with the leading vehicle in a second communication mode, where the second communication mode is a communication mode in which a network device performs forwarding.

Abstract: Provided is a method for preparing 2-hydroxy-4-(2, 3-disubstituted benzyloxy)-5-substituted benzaldehyde derivative represented by formula (I). The method comprises the following steps: (1) preparing 3-aryl-2-substituted toluene derivative 2 by using 3-iodo-2-substituted toluene derivative 1 and aryl boronic acid 5 or aryl boronate as starting materials; (2) preparing a benzyl halide derivative 3 by using 3-aryl-2-substituted toluene derivative 2 as starting materials; and (3) preparing 4-(2, 3-disubstituted benzyloxy)-2-hydroxy-5-substituted benzaldehyde derivative (I) by using benzyl halide derivative 3 and 2,4-dihydroxy-5-substituted benzaldehyde 6.

Abstract: Provided is a method for preparing 2-hydroxy-4-(2, 3-disubstituted benzyloxy)-5-substituted benzaldehyde derivative represented by formula (I). The method comprises the following steps: (1) preparing 3-aryl-2-substituted toluene derivative 2 by using 3-iodo-2-substituted toluene derivative 1 and aryl boronic acid 5 or aryl boronate as starting materials; (2) preparing a benzyl halide derivative 3 by using 3-aryl-2-substituted toluene derivative 2 as starting materials; and (3) preparing 4-(2, 3-disubstituted benzyloxy)-2-hydroxy-5-substituted benzaldehyde derivative (I) by using benzyl halide derivative 3 and 2,4-dihydroxy-5-substituted benzaldehyde 6.

Abstract: A communication mode switching method, a network side device, and a terminal device includes a communication mode of the second vehicle to everything (V2X) service is switched from a first communication mode to the second communication mode for scheduling a first V2X service of a radio resource to be transmitted using the first communication mode.

Abstract: The present invention discloses a nicotinyl alcohol ether derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to nicotinyl alcohol ether derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.

Abstract: The present invention discloses a phenylate derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to phenylate derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.

Abstract: Provided are a use of chlorogenic acid in preparing pharmaceuticals for the inhibition of LAG-3 and a use of chlorogenic acid in preparing pharmaceuticals for the treatment of LAG-3-mediated diseases. The inhibition of LAG-3 by chlorogenic acid is useful in cancer therapy, anti-viral therapy, and sepsis treatment.

Abstract: The present invention provides an application of chlorogenic acid in preparing medicines for treating melanoma and a pharmaceutical composition comprising chlorogenic acid and used for treating melanoma.

Abstract: The present invention provides an application of chlorogenic acid in preparing medicines for treating lupus erythematosus. The chlorogenic acid can improve an immunity function. The present invention provides a preparation for treating lupus erythematosus, comprising chlorogenic acid and pharmaceutically acceptable auxiliary materials. The present invention further provides a combined medicine comprising chlorogenic acid and medicines for treating lupus erythematosus.